IOVA | Iovance Biotherapeutics Inc Company profile
Company profileIovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. About the CompanyIovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lympocyte therapies against cancer. Address999 Skyway Road Key Persons / Board of Directors
| NotesJump to (Finance sites)         ResearchInvestor pagewww.iovance.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Homepage: iovance.comTheir Official Profiles   Other stocks            Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended Books Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals. |